NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: KRAS Gene Mutation
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Trametinib

First Posted Date: 2015-12-30

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT02642042

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

and more 596 locations

Measuring and Improving Medication Adherence in Kidney Transplant Patients

Not Applicable

Completed

Conditions: Kidney Transplant Recipients

Interventions: Behavioral: Standard Care
Behavioral: Cognitive-behavioral adherence promotion program

First Posted Date: 2015-12-28

Last Posted Date: 2017-09-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 45

Registration Number: NCT02639949

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

Phase 2

Completed

Conditions: Lipodystrophy

Interventions: Drug: Placebo
Drug: ISIS 304801

First Posted Date: 2015-12-24

Last Posted Date: 2020-10-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 5

Registration Number: NCT02639286

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

Phase 1

Completed

Conditions: Kidney Disease

Interventions: Drug: N-acetyl D-mannosamine

First Posted Date: 2015-12-24

Last Posted Date: 2023-02-24

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 10

Registration Number: NCT02639260

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Ductal Carcinoma In Situ

Interventions: Other: Laboratory Biomarker Analysis
Drug: Nelipepimut-S Plus GM-CSF Vaccine
Biological: Sargramostim
Procedure: Surgical Procedure

First Posted Date: 2015-12-22

Last Posted Date: 2023-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT02636582

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States

and more 1 locations

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Malignant Solid Neoplasm

Interventions: Drug: Ferumoxytol
Drug: Irinotecan Sucrosofate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Veliparib

First Posted Date: 2015-12-16

Last Posted Date: 2025-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT02631733

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 3 locations

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Phase 2

Completed

Conditions: Adult T-Cell Leukemia/Lymphoma
Chronic Adult T-Cell Leukemia/Lymphoma
HTLV-1 Infection
Smoldering Adult T-Cell Leukemia/Lymphoma
Lymphomatous Adult T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Other: Pharmacogenomic Study

First Posted Date: 2015-12-16

Last Posted Date: 2025-03-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT02631746

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

and more 3 locations

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Ovarian Carcinoma
Platinum-Sensitive Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Stage IV Fallopian Tube Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Primary Peritoneal Cancer AJCC v7
Ovarian Endometrioid Tumor
Recurrent Primary Peritoneal Carcinoma
Metastatic Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Berzosertib
Drug: Carboplatin
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-12-11

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT02627443

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 11 locations

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Phase 1

Withdrawn

Conditions: Fallopian Tube Serous Neoplasm
Adult Solid Neoplasm
Ovarian Serous Adenocarcinoma
Ovarian Serous Tumor
Primary Peritoneal Serous Adenocarcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Hsp90 Inhibitor AT13387
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Talazoparib

First Posted Date: 2015-12-11

Last Posted Date: 2016-07-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02627430

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Biological: young TIL
Drug: Aldesleukin
Drug: Pembrolizumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2015-12-03

Last Posted Date: 2025-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 170

Registration Number: NCT02621021

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy